MGuard Stent and Microcirculation

GUARDIANCORY study is a multicentre, prospective, randomized, non inferiority, open-label trial with a planned inclusion of 52 patients with STE and NSTE ACS and prescribed PCI. Patients will be randomized to benefiting either DES /BMS implantation (n=26) or MGuard stent (n=26) on the culprit lesion. Assessment of coronary microcirculation will be done by IMR immediately after PCI by using a pressure-temperature sensor-tipped coronary wire, thermodilution-derived.

Inclusion criteria

• Age > 18 years
• Patients affiliated to social security
• Patients with an NSTEMI or STEMI (1)
• Thrombus containing coronary lesions on angiography (TIMI thrombus grade ≥ 3)
• Eligible patients for revascularization with angioplasty
• Patients consenting to participate in the study.

Exclusion criteria

• Age < 18 years
• Prior myocardial infarction
• Prior CABG
• Inability to comply with the protocol
• Major patient protected by law (article L1121-8),
• Person deprived of liberty (article L1121-8),
• Pregnant woman
• Breastfeeding women
• Patient with terminal illness,
• Terminal Renal failure
• Allergy to iodine
• Adenosine's contraindications: Asthmatic patients, Second- or third-degree AV block without a pacemaker or sick sinus syndrome. Systolic blood pressure less than 90mmHg. Recent use of dipyridamole or dipyridamole-containing medications, Methyl xanthenes such as aminophylline caffeine or theobromine block the effect of adenosine and should be held for at least 12 hours prior to the test. Known hypersensitivity to adenosine. Unstable acute myocardial infarction or acute coronary syndrome.